Viatris (NASDAQ:VTRS) (NASDAQ: VTRS) is a global diversified healthcare company formed in November 2020 through the combination of Mylan and Upjohn, a legacy division of Pfizer. Headquartered in North Wales, Pennsylvania, Viatris operates across the entire pharmaceutical value chain, from research and development to manufacturing, commercialization and supply chain management. The company’s mission centers on providing access to high-quality medicines in both developed and emerging markets, addressing the needs of patients across a wide range of therapeutic areas.
The company’s core business pillars include branded medicines, generic and biosimilar products, over-the-counter consumer health solutions, and novel regulatory services. Viatris leverages a broad pipeline of off-patent and on-patent products, focusing on specialties such as cardiology, oncology support, immunology, central nervous system disorders and infectious diseases. Its biosimilar portfolio features treatments designed to increase affordability and access to biologic therapies for patients with autoimmune conditions and cancer.
Viatris maintains a global manufacturing network with facilities in North America, Europe, Asia and Latin America, ensuring supply chain resilience and regulatory compliance. In addition to traditional pharmaceutical products, the company offers digital health and adherence solutions to support patients and healthcare providers, aiming to improve treatment outcomes through integrated care pathways and technology-enabled services.
Supported by a leadership team led by President and Chief Executive Officer Michael Goettler, Viatris employs approximately 45,000 people in more than 165 countries and territories. The company’s strategic priorities include expanding access to medicines, optimizing its diversified product portfolio and driving sustainable growth through disciplined capital allocation and operational excellence.
